Skip to content
Download PDF

Common Atrial Flutter and Macroreentrant and Multifocal Atrial Tachycardias

Chapter 257 | Part 6: Disorders of the Cardiovascular System · Part 6 – Cardiovascular Disorders · Chapter 257

Key Clinical Points

  1. Common atrial flutter is cavotricuspid isthmus (CTI)-dependent with counterclockwise activation, producing negative sawtooth flutter waves in leads II, III, and aVF.
  2. Atrial flutter rate is typically 240–300 beats/min, often conducting with 2:1 AV block to create regular tachycardia at 140–150 beats/min.
  3. Catheter ablation of the CTI is first-line therapy for atrial flutter, with a >95% success rate and low complication risk.
  4. Multifocal atrial tachycardia (MAT) requires ≥3 distinct P-wave morphologies with rates of 100–150 beats/min; it is commonly seen in patients with chronic pulmonary disease.
  5. MAT management focuses on treating underlying disease and correcting metabolic abnormalities; electrical cardioversion is ineffective for MAT.
  6. Antiarrhythmic drugs (flecainide, propafenone, amiodarone) may promote atrial flutter rather than fibrillation by slowing atrial conduction velocity.
  7. Anticoagulation is crucial for all atrial flutter patients based on CHA2DS2-VASc scoring, similar to atrial fibrillation.
  8. Up to 50% of patients undergoing CTI ablation develop recurrent atrial arrhythmias, most commonly atrial fibrillation.

DEFINITION & OVERVIEW

• Common Atrial Flutter: ◦ Also known as cavotricuspid isthmus (CTI)-dependent atrial flutter. ◦ Mechanism: A wavefront of electrical propagation encircling the tricuspid valve annulus, bounded anteriorly by the annulus and posteriorly by the inferior vena cava and the Eustachian ridge. ◦ Key Feature: The circuit passes through the sub-Eustachian or cavotricuspid isthmus, making it susceptible to interruption by catheter ablation.

• Macroreentrant Atrial Tachycardias (Atypical): ◦ Definition: Not dependent on conduction through the cavotricuspid isthmus; also known as 'non-cavotricuspid isthmus–dependent' atrial flutters. ◦ Clinical Context: ◦ Almost universally associated with areas of atrial scar. ◦ Right atrial atypical flutter: Often occurs after cardiac surgery involving an atriotomy in the right atrium. ◦ Left atrial flutter and perimitral left atrial fibrillation: Commonly seen after extensive left atrial ablation or mitral valve surgery.

• Multifocal Atrial Tachycardia (MAT): ◦ Definition: Characterized by a rhythm with at least three distinct P-wave morphologies, with rates typically from 100 to 150 beats/min. ◦ Key Features: ◦ Unlike atrial fibrillation, MAT exhibits clear isoelectric intervals between P waves. ◦ The atrial rate tends to be slower than in atrial fibrillation. ◦ Commonly observed in patients with chronic pulmonary disease and acute illnesses.

ETIOLOGY & PATHOPHYSIOLOGY

• Typical Atrial Flutter Mechanism: ◦ Counterclockwise rotation (most common) → produces negative sawtooth flutter waves in leads II, III, and aVF; positive P waves in lead V. ◦ Reverse typical atrial flutter: Clockwise rotation → opposite P-wave vector in inferior leads. ◦ Atrial rate: Typically 240–300 beats/min (may be slower with atrial disease or antiarrhythmic drugs). ◦ AV Conduction: Often conducts with 2:1 atrioventricular (AV) block, creating a regular tachycardia at 140–150 beats/min. ◦ Diagnostic Maneuver: Maneuvers that increase AV nodal block (e.g., drugs or pacing) will typically expose flutter waves by increasing the conduction ratio.

• Atypical Atrial Flutter Mechanism: ◦ Not dependent on conduction through the cavotricuspid isthmus; associated with atrial scar. ◦ Often difficult to distinguish from focal AT; confirmation usually requires an electrophysiology study.

• Multifocal Atrial Tachycardia (MAT) Mechanism: ◦ Triggered automaticity originating from multiple atrial foci. ◦ Characterized by distinct isoelectric intervals between P waves and a slower atrial rate (100–150 beats/min).

• Antiarrhythmic Drug Effects on Arrhythmia Presentation: ◦ Drugs such as flecainide, propafenone, or amiodarone may promote atrial flutter rather than fibrillation. ◦ Mechanism: These agents slow atrial conduction velocity and can promote reentry while suppressing ectopic atrial triggers.

CLINICAL FEATURES

• ECG Findings in Atrial Flutter: ◦ Sawtooth pattern of atrial activation. ◦ Negative flutter (F) waves in inferior limb leads; positive F waves in lead V. ◦ 4:1 atrioventricular (AV) conduction during flutter (may be harder to discern from T wave). ◦ Maneuvers increasing AV nodal block typically expose the flutter waves.

• ECG Findings in Multifocal Atrial Tachycardia: ◦ Irregular rhythm with ≥3 distinct P-wave morphologies. ◦ Clear isoelectric intervals between P waves. ◦ Atrial rate typically 100–150 beats/min.

• Hemodynamic Status: ◦ Hemodynamically unstable → Immediate cardioversion. ◦ Stable patients → Managed with rate control (AV nodal-blocking agents) or rhythm control strategies.

• Associated Conditions: ◦ Atrial flutter: Often associated with atrial scarring from senescence or prior cardiac surgery. ◦ MAT: Commonly observed in patients with chronic pulmonary disease and acute illnesses. ◦ Amiodarone in MAT: May be used, but long-term therapy is avoided due to risk of pulmonary fibrosis.

DIFFERENTIAL DIAGNOSIS

• Wide-Complex Tachycardia (WCT) Differential: ◦ Potential causes: Ventricular tachycardia, PSVT with bundle branch block aberrancy, or preexcited tachycardia. ◦ Management Rule: Treat as ventricular tachycardia until proven otherwise. ◦ Stable and Regular → Trial of intravenous adenosine is reasonable. ◦ Very Irregular → Likely preexcited AF or flutter; manage with cardioversion, intravenous procainamide, or ibutilide. ◦ Monitoring: Continuous ECG monitoring must be implemented; emergency cardioversion/defibrillation must be available.

• Atrial Fibrillation vs. Atrial Flutter: ◦ Transition: AF may precede flutter due to a line of functional block or coalescence of fibrillatory wavelets at anatomical barriers (crista terminalis, Eustachian valve). ◦ Drug Effect: Flecainide, propafenone, and amiodarone can promote atrial flutter over fibrillation by slowing conduction velocity.

• Atrial Flutter vs. Multifocal Atrial Tachycardia: ◦ Atrial Flutter: Regular tachycardia; sawtooth waves; rate 240–300 bpm; often 2:1 conduction. ◦ MAT: Irregular rhythm; ≥3 P-wave morphologies; rate 100–150 bpm; common in pulmonary disease; electrical cardioversion is ineffective.

INVESTIGATIONS & DIAGNOSIS

• ECG Diagnostic Criteria: ◦ Typical Atrial Flutter: Negative sawtooth waves (II, III, aVF); positive waves (V); rate 240–300; often 2:1 conduction. ◦ Reverse Typical: Opposite P-wave vector in inferior leads. ◦ MAT: ≥3 distinct P-wave morphologies; rate 100–150; clear isoelectric intervals.

• Anticoagulation Risk Assessment: Assessment based on CHA2DS2-VASc score and bleeding risk. Anticoagulation is crucial before considering rhythm control. Table 1 — CHA2DS2-VASc Scoring System for Atrial Flutter: ◦ Congestive heart failure/LV dysfunction: 1 ◦ Hypertension: 1 ◦ Age ≥75 years: 2 ◦ Diabetes mellitus: 1 ◦ Stroke/TIA/thromboembolism: 2 ◦ Vascular disease: 1 ◦ Age 65–74 years: 1 ◦ Sex category (female): 1

• Diagnostic Algorithm: 1. Assess hemodynamic stability → Unstable → Immediate cardioversion. 2. Stable → Determine anticoagulation need based on CHA2DS2-VASc score. 3. Choose strategy: Rate control (calcium channel blocker, digoxin, beta-blocker) or rhythm control (antiarrhythmic drug therapy, catheter ablation). 4. Consider catheter ablation as first-line therapy for rhythm control. 5. Monitor for recurrence and development of atrial fibrillation.

• Electrophysiology Study Indications: ◦ Required to confirm mechanism of atypical atrial flutter. ◦ Used to map CTI-dependent circuits (e.g., identifying counterclockwise rotation). ◦ Guided by electroanatomic mapping (EAM) where 'early meets late' (red-purple) identifies the target for radiofrequency ablation in the CTI. ◦ Cycle length during flutter is typically around 260 ms.

MANAGEMENT & TREATMENT

• Acute Management: 1. Hemodynamically unstable → Immediate cardioversion. 2. Hemodynamically stable → Vagal maneuvers or adenosine (caution in WPW/post-transplant). 3. Stable → Rate control with AV nodal-blocking agents (beta-blockers, calcium channel blockers).

• Adenosine Considerations: 1. Effective for PSVT; may cause transient chest pain, dyspnea, or anxiety. 2. Contraindicated in: Prior cardiac transplant (hypersensitivity) or potential bronchospasm. 3. Caution in WPW: May precipitate brief AF which can cause instability.

• Rate Control Therapy: 1. Calcium channel blockers (e.g., verapamil, diltiazem). 2. Beta-blockers. 3. Digoxin.

• Rhythm Control Therapy: 1. Antiarrhythmic drugs (AAD): Flecainide, propafenone, amiodarone. 2. Catheter ablation: First-line therapy for atrial flutter; success rate >95%; low complication risk. 3. Note: Over 70% of patients on AAD therapy experience recurrences.

• Multifocal Atrial Tachycardia Treatment: 1. Primary focus: Treat underlying disease and correct metabolic abnormalities. 2. Rate control: Verapalam, diltiazem (beta-blockers often poorly tolerated in severe pulmonary disease). 3. Amiodarone: May be used but long-term therapy avoided due to risk of pulmonary fibrosis.

• Catheter Ablation Details: 1. First-line for rhythm control in atrial flutter. 2. Success rate >95% with low complication risk. 3. Note: Up to 50% of patients may develop other arrhythmias, most commonly atrial fibrillation, after CTI ablation. 4. Pulmonary vein isolation (PVI) as first-line therapy can prevent recurrence and reduce new-onset AF risk.

Treatment algorithm for patients presenting with hemodynamically stable paroxysmal supraventricular tachycardia

  1. Start → Regular narrow-complex tachycardia.
  2. Hemodynamically unstable? → Yes → Cardioversion → If Recurrent → Catheter ablation.
  3. Hemodynamically unstable? → No → Vagal reflex/adenosine.
  4. If "Ineffective" → Non-DHP CCB and/or Beta blocker.
  5. If "Ineffective" → Antihyarrhythmic therapy.
  6. If "Recurrent or incessant" → Catheter ablation.

Approach to the patient with atrial flutter

  1. Typical Atrial Flutter → Anticoagulation (based on CHA2DS2-VASc score and if a definite treatment is planned).
  2. Decision: Rate control or rhythm control with AAD.
  3. Path: Rate control → Amiodarone, Beta blocker, Calcium channel blocker, Digoxin → Poor response → [Next Step].
  4. Path: Rhythm control → Cardioversion (if Hemodynamically unstable OR Severe symptoms).
  5. Path: Rhythm control → Catheter ablation → First-line therapy → Decision: CTI ablation OR PV1 ablation (based on success rate).
  6. Risk Assessment Branch: ◦ Known AF → High-risk TE profile → Consider anticoagulation for high-risk features. ◦ No known AF → Low-risk TE profile → Monitor anticoagulation (clinical follow-up and arrhythmia monitoring).

PROGNOSIS & COMPLICATIONS

• Thromboembolic Risk: ◦ Anticoagulation is crucial before considering rhythm control strategies. ◦ Based on CHA2DS2-VASc; risk in MAT is not considered the same as AF or atrial flutter.

• Recurrence Rates: ◦ AAD therapy: >70% recurrence rate. ◦ Catheter ablation: >95% success rate with low complication risk. ◦ Note: Up to 50% of CTI ablation patients develop other arrhythmias (most commonly AF).

• Long-term Follow-up: ◦ Monitor off anticoagulation with clinical follow-up and arrhythmia monitoring. ◦ Research ongoing for better ablation strategies to reduce new-onset AF.

SPECIAL CONSIDERATIONS

• Antiarrhythmic Drug Selection: ◦ Flecainide, propafenone, amiodarone. ◦ Amiodarone: Avoid long-term in MAT due to pulmonary fibrosis risk.

• Beta-Blocker Considerations: ◦ Patients with severe pulmonary disease often do not tolerate beta-blockers well (relevant for MAT management).

• Adenosine Contraindications: ◦ Prior cardiac transplant → potential hypersensitivity from surgical sympathetic denervation. Note: Also potentially problematic in patients with risk of bronchospasm.

KEY PEARLS & CLINICAL TRAPS

• Diagnostic Pearls: ◦ Maneuvers increasing AV block (e.g., adenosine, drugs) help identify flutter waves. ◦ Very irregular wide-complex tachycardia → likely preexcited AF/flutter → manage with cardioversion or procainamide.

• Treatment Pearls: ◦ Catheter ablation is first-line for atrial flutter due to high success (>95%). ◦ Electrical cardioversion is ineffective in MAT.

• Antiarrhythmic Drug Pearls: ◦ Drugs like flecainide/propafenone can promote flutter by slowing conduction velocity.

• Anticoagulation Pearls: ◦ Anticoagulation must be established before rhythm control strategies are initiated.